New Trends and Advances in Diagnosis and Prognosis of Head and Neck Cancer from Carcinogenesis to Future Molecular Targeted Therapies II

Dear Colleagues, 

Head and neck cancer is a heterogenous malignancy with high mortality and increasing incidence worldwide. Late diagnosis, rapid tumour growth, poor response to radiochemotherapy and early local recurrence are still key challenges in modern treatment. Growing evidence suggests that the highly aggressive behaviour of head and neck cancer may be an effect of cancer stem cells and abnormalities in the signalling pathways associated with them. Despite recent advances in therapeutic strategies, the 5-year survival rate has remained stable in recent decades at about 50%. For this reason, further studies elucidating head and neck cancer biology are urgently required to improve the survival of patients.
    
We are delighted to present this Special Issue of Cells that is focused on the latest advances and future trends in the diagnosis, prognosis and treatment of head and neck cancer. This Special Issue will present original research articles as well as up-to-date review papers that present cellular and molecular mechanisms of head and neck cancer and, in particular, new specific biomarkers or potential therapy targets that may allow us to better stratify the prognosis of patients and improve their clinical outcome. We would like to encourage head and neck cancer researchers around the world to submit their manuscripts to this Special Issue.

Dr. Piotr Cierpikowski
Dr. Nina Zidar
Prof. Dr. Julia Bar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• head and neck cancer
• oral cancer
• biomarker
• prognosis
• carcinogenesis
• oral premalignant lesions
• cancer stem cells
• signaling pathways
• molecular targeted therapy

• New Trends and Advances in Diagnosis and Prognosis of Head and Neck Cancer from Carcinogenesis to Future Molecular Targeted Therapies in Cells (10 articles)